$2.6T
Total marketcap
$169.2B
Total volume
BTC 49.99%     ETH 15.81%
Dominance

Travere Therapeutics TVTX Stock

7.18 USD {{ price }} -4.138851% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
546.39M USD
LOW - HIGH [24H]
7.14 - 7.47 USD
VOLUME [24H]
1.02M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-5.07 USD

Travere Therapeutics Price Chart

Travere Therapeutics TVTX Financial and Trading Overview

Travere Therapeutics stock price 7.18 USD
Previous Close 16.92 USD
Open 16.92 USD
Bid 0 USD x 800
Ask 0 USD x 800
Day's Range 16.61 - 17.28 USD
52 Week Range 14.51 - 29.14 USD
Volume 1.28M USD
Avg. Volume 1.38M USD
Market Cap 1.28B USD
Beta (5Y Monthly) 0.458098
PE Ratio (TTM) N/A
EPS (TTM) -5.07 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 28.29 USD

TVTX Valuation Measures

Enterprise Value 1.11B USD
Trailing P/E N/A
Forward P/E -6.666667
PEG Ratio (5 yr expected) -0.02
Price/Sales (ttm) 5.819122
Price/Book (mrq) 6.782335
Enterprise Value/Revenue 5.023
Enterprise Value/EBITDA -4.63

Trading Information

Travere Therapeutics Stock Price History

Beta (5Y Monthly) 0.458098
52-Week Change -30.58%
S&P500 52-Week Change 20.43%
52 Week High 29.14 USD
52 Week Low 14.51 USD
50-Day Moving Average 18.43 USD
200-Day Moving Average 21.1 USD

TVTX Share Statistics

Avg. Volume (3 month) 1.38M USD
Avg. Daily Volume (10-Days) 1.36M USD
Shares Outstanding 74.61M
Float 56.57M
Short Ratio 4.29
% Held by Insiders 1.29%
% Held by Institutions 102.75%
Shares Short 7.3M
Short % of Float 9.83%
Short % of Shares Outstanding 9.77%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -130.97%
Operating Margin (ttm) -124.61%
Gross Margin -12.31%
EBITDA Margin -108.50%

Management Effectiveness

Return on Assets (ttm) -20.98%
Return on Equity (ttm) -145.40%

Income Statement

Revenue (ttm) 220.52M USD
Revenue Per Share (ttm) 3.39 USD
Quarterly Revenue Growth (yoy) 17.50%
Gross Profit (ttm) -31354000 USD
EBITDA -239268000 USD
Net Income Avi to Common (ttm) -288841984 USD
Diluted EPS (ttm) -4.38
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 561.51M USD
Total Cash Per Share (mrq) 7.53 USD
Total Debt (mrq) 406.84M USD
Total Debt/Equity (mrq) 215.1 USD
Current Ratio (mrq) 4.63
Book Value Per Share (mrq) 2.536

Cash Flow Statement

Operating Cash Flow (ttm) -212088000 USD
Levered Free Cash Flow (ttm) -153457504 USD

Profile of Travere Therapeutics

Country United States
State CA
City San Diego
Address 3611 Valley Centre Drive
ZIP 92130
Phone 888 969 7879
Website https://www.travere.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 462

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Q&A For Travere Therapeutics Stock

What is a current TVTX stock price?

Travere Therapeutics TVTX stock price today per share is 7.18 USD.

How to purchase Travere Therapeutics stock?

You can buy TVTX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Travere Therapeutics?

The stock symbol or ticker of Travere Therapeutics is TVTX.

Which industry does the Travere Therapeutics company belong to?

The Travere Therapeutics industry is Biotechnology.

How many shares does Travere Therapeutics have in circulation?

The max supply of Travere Therapeutics shares is 76.1M.

What is Travere Therapeutics Price to Earnings Ratio (PE Ratio)?

Travere Therapeutics PE Ratio is now.

What was Travere Therapeutics earnings per share over the trailing 12 months (TTM)?

Travere Therapeutics EPS is -5.07 USD over the trailing 12 months.

Which sector does the Travere Therapeutics company belong to?

The Travere Therapeutics sector is Healthcare.

Travere Therapeutics TVTX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Global Market Composite NQGM 2185.85 USD
-0.31
2177.48 USD 2204.21 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD